Raloxifene (Evista), a "designer estrogen" from Lilly
July 1997
There's lots of interest in raloxifene (Evista), a "designer estrogen" from Lilly. It has been covered on TV, in the news, etc.
It's being tested to prevent osteoporosis in postmenopausal women...as an alternative to using estrogen.
Raloxifene is a "selective estrogen receptor modulator"...it has both estrogen agonist AND antagonist effects.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote